Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Acrocephalosyndactylia 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Neoplasms 1Liver Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × derazantinib × Clear all
NCT04604132 2024-04-04

FIDES-03

Basilea Pharmaceutica

Phase 1/2 Terminated
47 enrolled 22 charts
Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT04045613 2023-10-13

FIDES-02

Basilea Pharmaceutica

Phase 1/2 Completed
95 enrolled 25 charts
Genitourinary

Acrocephalosyndactylia, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01752920 2023-06-05

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

Basilea Pharmaceutica

Phase 1/2 Completed
119 enrolled 15 charts
Gastrointestinal

Biliary Tract Neoplasms, Liver Neoplasms, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡